Routine medication use, as-needed medication use and psychotherapeutic medication usage across nursing facilities will be evaluated in a study sponsored by the American Society of Consultant Pharmacists' Research and Education Foundation, Alexandria, VA.
Routine medication use, as-needed medication use and psychotherapeutic medication usage across nursing facilities will be evaluated in a study sponsored by the American Society of Consultant Pharmacists' Research and Education Foundation, Alexandria, VA.
The 1997 National Medication Usage Study, the third of its kind, will update findings from the most recent investigation in 1994, according to Janice Feinberg, executive director of the society's research foundation.
Study coordinator Dianne Tobias, president of Tobias Consulting Services, Placentia, CA, will interpret medication use data submitted last month by Canadian and U.S. nursing facilities and consultant pharmacists.
At press time, nursing facilities and consultant pharmacists were scheduled to receive their usage statistics and regional and national averages by May 31.
The society will release its findings later this year.
According to the society, the data analysis will help long-term care pharmacists strategize consulting, provide facilities with comparative data useful for continuous quality improvement and allow providers to benchmark individual practices.
"The study will help facilities, pharmacists and physicians do an apples-to-apples comparison of their data [compared with] other facilities," said Tobias. It will also stimulate other facilities that did not participate in the study to review and assess the appropriateness of their medication use, she said.
The study's findings will be particularly useful for facilities operating as part of a managed care network, Tobias said.
"If a facility or consultant pharmacist is paid under capitation, it will be to everyone's benefit to use fewer drugs," she said.
"Capitation creates an incentive to optimize as well as minimize drug use on both the provider and patient side," Tobias said. PR
Pfizer, GSK Gain ACIP Recommendations for RSV and Meningococcal Vaccines
April 18th 2025The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted to expand access to Pfizer’s respiratory syncytial virus vaccine Abrysvo for high-risk adults in their 50s and voted in favor of GSK’s meningococcal vaccine, Penmenvy, for streamlined adolescent protection.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Study: GLP-1, SGLT2s Linked to Reduced Alzheimer Disease Risk in Patients with Type 2 Diabetes
April 17th 2025A new study found that patients with type 2 diabetes treated with GLP-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors demonstrated lower risks of developing Alzheimer disease compared to other glucose-lowering drugs.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
New Insights Into T Cell Exhaustion and Inflammation in Long COVID
April 17th 2025Nigel McCracken, chief operating officer, Virax Biolabs, discusses new findings that reveal altered cytokine activity and evidence of T cell exhaustion in long COVID patients, providing deeper insight into post-infection immune disruption.